Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Andreas Seeber"'
Autor:
Dominik Wolf, Andreas Seeber, Katharina Kurz, Florian Kocher, Arno Amann, Kai Zimmer, Andreas Pircher, Simon Geisler, Dietmar Fuchs, Renate Pichler
Publikováno v:
Transl Lung Cancer Res
Background Metabolic profiling in non-small cell lung cancer (NSCLC) may identify key metabolic vulnerabilities and shows enormous discovery potential. Preclinical studies showed that metabolic rewiring in cancer plays an essential role in modulation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd5923d44bf0b8893b1c0b7a7f06a07d
https://europepmc.org/articles/PMC7867793/
https://europepmc.org/articles/PMC7867793/
Publikováno v:
Oncology Research and Treatment. 41:188-193
Angiogenesis is a hallmark of cancer and is regulated by a balance of pro- and anti-angiogenic factors; among them, the vascular endothelial growth factor (VEGF) is the key angiogenic factor. VEGF plays an important role in colorectal cancer (CRC) bi
Autor:
Andreas Seeber, Luigi Terracciano, Alessandro Lugli, Florian Kocher, Gerold Untergasser, Armin Kasal, Guido Mazzoleni, Gilbert Spizzo, Normann Steiner, Dominic Fong, Guenther Gastl
Publikováno v:
International Journal of Cancer. 139:657-663
Regulated intramembrane proteolysis (RIP) has been shown to be an important mechanism for oncogenic activation of EpCAM through nuclear translocation of the intracellular domain EpICD. Recently, we identified two different membranous EpCAM variants n
Autor:
Andreas Seeber, Günther Gastl
Publikováno v:
Oncology Research and Treatment. 39:796-802
Over the past decades, considerable progress has been made in the management of colorectal cancer (CRC), leading to a significant improvement in overall survival. Although part of this success has been rightly attributed to aggressive surgical manage
Publikováno v:
Stem Cells Translational Medicine
Colorectal cancer (CRC) is one of the most common malignancies worldwide. In spite of various attempts to ameliorate outcome by escalating treatment, significant improvement is lacking particularly in the adjuvant setting. It has been proposed that c
Autor:
Kathrin Philipp-Abbrederis, Christoph Leitner, Gilbert Spizzo, Andreas Seeber, Florian Kocher
Publikováno v:
Future oncology (London, England). 13(16)
Systemic therapy options for small cell lung cancer patients with extensive disease remain poor. After an initial response on first-line therapy, virtually all patients develop disease progression. For those who showed an initial response only few th